Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | AR | P10275 | 6/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | MMP14 | P50281 | 1/20 | 0.52 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5380794 | 0.91 | SMN1; SMN2 (0.58) | POLBMEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL5378723 | 0.89 | POLB (0.69) | POLBMEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL5380382 | 0.89 | MEN1 (0.77) | POLBMEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL5373270 | 0.89 | POLB (0.63) | POLBMEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL5378751 | 0.86 | MEN1 (0.72) | POLBMEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL5376847 | 0.86 | AR (0.66) | POLBMEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL4904177 | 0.86 | MMP2 (0.53) | POLBMEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL5372119 | 0.86 | POLB (0.62) | POLBMEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL5380688 | 0.85 | POLB (0.64) | POLBMEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL5367846 | 0.84 | POLB (0.60) | POLBMEN1KMT2APKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262318-B2 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262318-B2 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262318-B2 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20050228015-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228015-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PPARA, PPARG, PPARD | POLB 1807/4885MEN1 4855/4885KMT2A 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.